Literature DB >> 192617

Potentiation of the hepatic action of insulin by chlorpropamide.

S A Blumenthal.   

Abstract

In perfused livers of fed rats, chlorpropamide inhibits glucagon-stimulated glucose production by augmenting the action of insulin. This effect is associated with a decrease in cyclic AMP accumulation in liver and perfusate. Alterations in glucose production appear to correlate more closely with changes in the amount of cyclic AMP in the perfusate than with changes in intrahepatic concentration of nucleotide. Potenitation by chlorpropamide of the hepatic action of insulin does not require administration of the drug prior to perfusion. Further, it is demonstrable at concentrations of insulin and glucagon (10(-11M) that approximate the normal plasma levels of these hormones.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 192617     DOI: 10.2337/diab.26.5.485

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  8 in total

1.  [Mechanism of action of combined administration of glibenclamide and insulin in type II diabetics with secondary failure of oral treatment].

Authors:  F H Schmidt; J Klujko; H F Kühnle; J Reiter
Journal:  Klin Wochenschr       Date:  1986-10-15

2.  Effects of the combination of insulin and glibenclamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral hypoglycaemic agents.

Authors:  S Stenman; P H Groop; C Saloranta; K J Tötterman; F Fyhrqvist; L Groop
Journal:  Diabetologia       Date:  1988-04       Impact factor: 10.122

3.  Sulphonylureas in vitro do not alter insulin binding or insulin effect on amino acid transport in rat hepatocytes.

Authors:  J Dolais-Kitabgi; F Alengrin; P Freychet
Journal:  Diabetologia       Date:  1983-06       Impact factor: 10.122

Review 4.  Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 2.

Authors:  J E Jackson; R Bressler
Journal:  Drugs       Date:  1981-10       Impact factor: 9.546

5.  Tolbutamide does not alter insulin requirement in Type 1 (insulin-dependent) diabetes.

Authors:  K P Ratzmann; B Schulz; P Heinke; W Besch
Journal:  Diabetologia       Date:  1984-07       Impact factor: 10.122

6.  Selective potentiation of insulin-mediated glucose disposal in normal dogs by the sulfonylurea glipizide.

Authors:  W S Putnam; D K Andersen; R S Jones; H E Lebovitz
Journal:  J Clin Invest       Date:  1981-04       Impact factor: 14.808

7.  Sulfonylureas and their use in clinical practice.

Authors:  Daniele Sola; Luca Rossi; Gian Piero Carnevale Schianca; Pamela Maffioli; Marcello Bigliocca; Roberto Mella; Francesca Corlianò; Gian Paolo Fra; Ettore Bartoli; Giuseppe Derosa
Journal:  Arch Med Sci       Date:  2015-08-11       Impact factor: 3.318

8.  Antidiabetic and Antihyperlipidemic Effects of Sulphurenic Acid, a Triterpenoid Compound from Antrodia camphorata, in Streptozotocin-Induced Diabetic Mice.

Authors:  Cheng-Hsiu Lin; Li-Wei Hsiao; Yueh-Hsiung Kuo; Chun-Ching Shih
Journal:  Int J Mol Sci       Date:  2019-10-02       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.